MedStar Authors catalog › Details for: Outcome of implantation of a second self-expanding valve for the treatment of residual significant aortic regurgitation.
Outcome of implantation of a second self-expanding valve for the treatment of residual significant aortic regurgitation. Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.Published: 2017ISSN: 1522-1946.UI/PMID: 28296039.Subject(s): Aged | Aged, 80 and over | Aortic Valve/dg [Diagnostic Imaging] | Aortic Valve/pp [Physiopathology] | *Aortic Valve/su [Surgery] | Aortic Valve Insufficiency/dg [Diagnostic Imaging] | Aortic Valve Insufficiency/et [Etiology] | Aortic Valve Insufficiency/pp [Physiopathology] | *Aortic Valve Insufficiency/su [Surgery] | Aortic Valve Stenosis/dg [Diagnostic Imaging] | Aortic Valve Stenosis/pp [Physiopathology] | *Aortic Valve Stenosis/su [Surgery] | Female | *Heart Valve Prosthesis | Hemodynamics | Humans | Male | Prosthesis Design | Risk Factors | Time Factors | Transcatheter Aortic Valve Replacement/ae [Adverse Effects] | *Transcatheter Aortic Valve Replacement/is [Instrumentation] | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1002/ccd.26960 (Click here) Abbreviated citation: Catheter Cardiovasc Interv. 90(4):673-679, 2017 Oct 01.Local Holdings: Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006.Abstract: BACKGROUND: Residual aortic regurgitation (AR) following transcatheter aortic valve replacement (TAVR) is associated with adverse outcome. We sought to evaluate the efficacy and safety of second CoreValve (CV) implantation to treat residual AR following the initial CV deployment.Abstract: METHODS AND RESULTS: TAVR patients treated with a second CV due to moderate and above residual AR were compared to single device implantation. Valvular function parameters were compared at baseline, post procedure, and 30 days. Among 172 CV TAVR patients, 11 required a second device (6%) due to significant residual AR. The main differences between the groups were higher rates of low ejection fraction in patients with 2 CV implanted and higher annular diameter (27 [29-25] vs. 25 [26-24] mm, P=0.03), requiring a larger device. Although two patients in the two CV group had high initial implantation, low implantation was similar between the groups. A second CV achieved adequate reduction in residual AR in six patients (55%), while an additional four patients had moderate residual AR. Only one remained with moderate to severe AR after 30 days follow-up. There were no cases of peri-procedural stroke or mortality.Abstract: CONCLUSIONS: Second implantation of self-expanding valve can successfully reduce residual significant AR following initial CV implantation and should be considered as therapeutic option for this population. � 2017 Wiley Periodicals, Inc.Abstract: Copyright � 2017 Wiley Periodicals, Inc.